Drugs / LB1410
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05357651 | Aug 2022 → Dec 2026 expected | cancer, lymphoma | L & L Bio Co., Ltd., Ningbo, China | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06468358 | Jun 2024 → Dec 2026 expected | cancer | L & L Bio Co., Ltd., Ningbo, China | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07177716 | Oct 2025 → Dec 2028 expected | cervical cancer | L & L Bio Co., Ltd., Ningbo, China | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB1410 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07177716 ↗ |
| Route | Intravenous | “LB1410 administered intravenously (IV)” NCT05357651 ↗ |